Press release
Spinal Muscular Atrophy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme
The Spinal Muscular Atrophy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
"Spinal Muscular Atrophy Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinal Muscular Atrophy Market.
Some of the key takeaways from the Spinal Muscular Atrophy Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Spinal Muscular Atrophy treatment therapies with a considerable amount of success over the years.
*
Spinal Muscular Atrophy companies working in the treatment market are Skyline Therapeutics, Exegenesis Bio, Biogen, GeneCradle Inc., Hangzhou Jiayin Biotech Ltd, Scholar Rock, Inc., Biohaven Pharmaceuticals, Inc, and others, are developing therapies for the Spinal Muscular Atrophy treatment
*
Emerging Spinal Muscular Atrophy therapies in the different phases of clinical trials are- SKG 0201, Spinal muscular atrophy gene therapy, BIIB115, GC101, EXG001-307, Apitegromab, Talditercept alfa, and others are expected to have a significant impact on the Spinal Muscular Atrophy market in the coming years.
*
In March 2025, Scholar Rock's spinal muscular atrophy (SMA) treatment demonstrated improvements in muscle function among children under 12 in a key clinical study, yet the results failed to excite investors. The Phase III SAPPHIRE trial (NCT05156320) assessed the safety and effectiveness of apitegromab, a monoclonal antibody designed to enhance muscle growth by targeting and inhibiting the inactive forms of myostatin specifically within skeletal muscle.
*
In February 2025, A pilot clinical trial suggested that spinal cord stimulation (SCS) may help restore function in patients with spinal muscular atrophy (SMA) by gradually activating dormant motor neurons and enhancing leg muscle strength. Conducted by the University of Pittsburgh School of Medicine (NCT05430113), the study evaluated Medtronic's Vectris SureScan device in three SMA patients. All participants demonstrated improved mobility, each increasing their distance in the six-minute walk test (6MWT)-a key indicator of muscle endurance-by at least 20 meters after three months of treatment.
*
In January 2025, Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company focused on developing novel therapies for spinal muscular atrophy (SMA), cardiometabolic conditions, and other serious diseases involving protein growth factors, has announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for apitegromab. This muscle-directed therapy is intended to deliver significant motor function improvement in individuals with SMA who are already receiving SMN-targeted treatments. The company also plans to submit a Marketing Authorisation Application to the European Medicines Agency in the first quarter of 2025.
*
In January 2025, Analytics firm GlobalData has expressed a positive outlook on the future of Novartis' gene therapy for spinal muscular atrophy (SMA), onasemnogene abeparvovec (OAV101 IT). The therapy may soon be accessible to a wider patient group, thanks to encouraging results from Novartis' Phase III STEER trial (NCT05089656), in which the intrathecal version of the treatment successfully met its primary endpoint.
*
In November 2024, Biohaven Ltd. (NYSE: BHVN), a global clinical-stage biopharmaceutical company dedicated to developing and commercializing transformative therapies for various rare and common diseases, announced updates on the development programs for taldefgrobep alfa in Spinal Muscular Atrophy (SMA) and obesity.
*
In November 2024, Scholar Rock (NASDAQ: SRRK), a late-stage biopharmaceutical company dedicated to developing innovative therapies for spinal muscular atrophy (SMA), cardiometabolic conditions, and other severe diseases driven by protein growth factors, has announced positive and statistically significant topline results from the pivotal Phase 3 SAPPHIRE trial. These findings highlight the potential of apitegromab to transform the standard of care for SMA patients.
*
In April 2024, Exegenesis Bio, a fast-expanding global leader in genetic medicine, has shared clinical efficacy and safety findings from its Phase 1/2 trial (EXG001-307) for Spinal Muscular Atrophy (SMA) Type I. The data was presented on May 8, 2024, during the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting in Baltimore, Maryland (poster #627).
Spinal Muscular Atrophy Overview
Spinal Muscular Atrophy (SMA) is a genetic neuromuscular disorder characterized by the progressive degeneration of motor neurons in the spinal cord and brainstem. Motor neurons are nerve cells responsible for controlling voluntary muscle movement. When these motor neurons degenerate, muscles weaken and atrophy, leading to difficulties with movement, muscle weakness, and potentially life-threatening respiratory problems.
Get a Free Sample PDF Report to know more about Spinal Muscular Atrophy Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/spinal-muscular-atrophy-sma-pipeline-insight [https://www.delveinsight.com/report-store/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Spinal Muscular Atrophy Drugs Under Different Phases of Clinical Development Include:
*
SKG 0201: Skyline Therapeutics
*
Spinal muscular atrophy gene therapy: Exegenesis Bio
*
BIIB115: Biogen
*
GC101: GeneCradle Inc.
*
EXG001-307: Hangzhou Jiayin Biotech Ltd
*
Apitegromab: Scholar Rock, Inc.
*
Talditercept alfa: Biohaven Pharmaceuticals, Inc
Spinal Muscular Atrophy Route of Administration
Spinal Muscular Atrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
Spinal Muscular Atrophy Molecule Type
Spinal Muscular Atrophy Products have been categorized under various Molecule types, such as
*
Monoclonal Antibody
*
Peptides
*
Polymer
*
Small molecule
*
Gene therapy
Spinal Muscular Atrophy Pipeline Therapeutics Assessment
*
Spinal Muscular Atrophy Assessment by Product Type
*
Spinal Muscular Atrophy By Stage and Product Type
*
Spinal Muscular Atrophy Assessment by Route of Administration
*
Spinal Muscular Atrophy By Stage and Route of Administration
*
Spinal Muscular Atrophy Assessment by Molecule Type
*
Spinal Muscular Atrophy by Stage and Molecule Type
DelveInsight's Spinal Muscular Atrophy Report covers around 20+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Spinal Muscular Atrophy product details are provided in the report. Download the Spinal Muscular Atrophy pipeline report to learn more about the emerging Spinal Muscular Atrophy therapies [https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Spinal Muscular Atrophy Therapeutics Market include:
Key companies developing therapies for Spinal Muscular Atrophy are - Genentech Inc, Chugai Pharmaceutical, Cytokinetics Inc., Ionis Pharmaceuticals Inc., Genzyme Corporation, Novartis International AG, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, PerkinElmer Inc., Pfizer Inc., UW Health, Novo Nordisk A/S, Cure SMA, Boehringer Ingelheim Gmbh, Biogen Inc, F. Hoffmann-La Roche AG, Catalyst Pharmaceutical, Salarius Pharmaceuticals Inc, Regeneron Pharmaceuticals Inc, Isis Pharmaceuticals Inc., PTC Therapeutics, Natera Inc, AstraZeneca PLC, and others.
Spinal Muscular Atrophy Pipeline Analysis:
The Spinal Muscular Atrophy pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Spinal Muscular Atrophy with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Spinal Muscular Atrophy Treatment.
*
Spinal Muscular Atrophy key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Spinal Muscular Atrophy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Spinal Muscular Atrophy market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Spinal Muscular Atrophy drugs and therapies [https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Spinal Muscular Atrophy Pipeline Market Drivers
*
Increase in prevalence of Spinal Muscular Atrophy, increasing number of clinical trials and government funding for R&D are some of the important factors that are fueling the Spinal Muscular Atrophy Market.
Spinal Muscular Atrophy Pipeline Market Barriers
*
However, lack of public knowledge of this rare medical condition, cost associated with the treatment and other factors are creating obstacles in the Spinal Muscular Atrophy Market growth.
Scope of Spinal Muscular Atrophy Pipeline Drug Insight
*
Coverage: Global
*
Key Spinal Muscular Atrophy Companies: Skyline Therapeutics, Exegenesis Bio, Biogen, GeneCradle Inc., Hangzhou Jiayin Biotech Ltd, Scholar Rock, Inc., Biohaven Pharmaceuticals, Inc, and others
*
Key Spinal Muscular Atrophy Therapies: SKG 0201, Spinal muscular atrophy gene therapy, BIIB115, GC101, EXG001-307, Apitegromab, Talditercept alfa, and others
*
Spinal Muscular Atrophy Therapeutic Assessment: Spinal Muscular Atrophy current marketed and Spinal Muscular Atrophy emerging therapies
*
Spinal Muscular Atrophy Market Dynamics: Spinal Muscular Atrophy market drivers and Spinal Muscular Atrophy market barriers
Request for Sample PDF Report for Spinal Muscular Atrophy Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/spinal-muscular-atrophy-sma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Spinal Muscular Atrophy Report Introduction
2. Spinal Muscular Atrophy Executive Summary
3. Spinal Muscular Atrophy Overview
4. Spinal Muscular Atrophy- Analytical Perspective In-depth Commercial Assessment
5. Spinal Muscular Atrophy Pipeline Therapeutics
6. Spinal Muscular Atrophy Late Stage Products (Phase II/III)
7. Spinal Muscular Atrophy Mid Stage Products (Phase II)
8. Spinal Muscular Atrophy Early Stage Products (Phase I)
9. Spinal Muscular Atrophy Preclinical Stage Products
10. Spinal Muscular Atrophy Therapeutics Assessment
11. Spinal Muscular Atrophy Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Spinal Muscular Atrophy Key Companies
14. Spinal Muscular Atrophy Key Products
15. Spinal Muscular Atrophy Unmet Needs
16 . Spinal Muscular Atrophy Market Drivers and Barriers
17. Spinal Muscular Atrophy Future Perspectives and Conclusion
18. Spinal Muscular Atrophy Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=spinal-muscular-atrophy-pipeline-2025-moa-and-roa-insights-clinical-trials-status-and-key-companies-involved-by-delveinsight-genentech-inc-chugai-pharma-cytokinetics-inc-ionis-pharma-genzyme]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Spinal Muscular Atrophy Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Genentech Inc, Chugai Pharma, Cytokinetics Inc., Ionis Pharma, Genzyme here
News-ID: 4023861 • Views: …
More Releases from ABNewswire
Big Kid Circus Brings the Spectacular 'Kingdom of Kong' Tour to Cumbernauld
The UK's most thrilling live circus experience, Big Kid Circus, is bringing its breathtaking Kingdom of Kong tour to Cumbernauld for a limited four-day run.
From Wednesday 25th June to Sunday 29th June, audiences will be transported into an awe-inspiring world of acrobatics, fire performances, and high-energy entertainment at Antonine Shopping Centre, Cumbernauld, Cumbernauld, G67 1JW.
This unmissable event promises fun for the whole family, with ticket prices starting at just 9.99.…
Rees Clayton Solicitors: Expert Legal Defence for Totting Up and Speeding Charge …
Rees Clayton Solicitors, a leading law firm with offices across Lancashire and London, offers specialised legal defence services for individuals facing totting up bans and speeding charges.
Understanding Totting Up Bans
In the UK, drivers accumulate penalty points on their licences for various offences, such as speeding or using a mobile phone while driving. Reaching 12 or more points within a three-year period typically results in a mandatory disqualification, known as a…
Happy Kombucha Offers a Diverse Range of Fermented Products to Boost Gut Health
In light of recent studies highlighting the benefits of fermented foods on the human microbiome, Happy Kombucha is proud to offer a wide array of products designed to support and enhance gut health.
A recent study has confirmed that cheese isn't just food-it's a microbiome booster. This research underscores the importance of incorporating fermented foods into our diets to promote a healthy gut microbiome.
Happy Kombucha provides a variety of fermented and…
Burleigh Travel Reports Surge in Rugby Tour Bookings Amid Six Nations Excitement
Burleigh Travel, a leading specialist in sports tours, has reported a significant increase in rugby tour bookings, driven by the heightened excitement surrounding the 2025 Six Nations Championship.
With the tournament captivating fans across Europe, rugby clubs, schools, and university teams are eager to experience their own overseas and domestic rugby tours, inspired by the thrilling international competition.
Unparalleled Rugby Tour Experiences
Burleigh Travel has been organising bespoke sports tours for over 30…
More Releases for Spinal
Spinal Non-Fusion
Spinal implants are devices used for the treatment of spinal disorders such as disproportion and instability of spine. Spine surgical devices are broadly classified into fusion and non-fusion devices. Fusion devices heals by providing immediate and rigid immobilization, and non-fusion devices treats by replacing pro-inflammatory tissues, restoring spinal alignment, and decompressing neural elements while preserving functional movements rather than obliterating it. The advantages such as prolonged recuperation time, bone graft…
Different Approaches to Spinal Fusion Market And Control Spinal Deformity Develo …
Spinal fusion is surgery to permanently join together two or more bones in the spine so there is no movement between them. For patients who require spinal fusion surgery to treat lumbar degenerative disc disease (DDD), spinal fusion device is a treatment option.
Spinal fusion has been used for many years to treat many painful conditions in the lumbar (lower) spine. Over the past decade, there has been dramatic improvement in…
Spinal Cord Compression-Spinal Stenosis Market Progresses for Huge Profits by 20 …
The Global Spinal Cord Compression-Spinal Stenosis Market is expected to reach $ 8.5 billion by the end of 2023, this market is projected to growing at a CAGR of ~ 11.5 % during 2017-2023.
Spinal stenosis is the abnormal narrowing of spinal canal causing it to restrict, which may result in a neurological deficit due to interference with neurological fibres. The associated symptoms include pain, numbness, loss of motor control etc.…
Spinal Cord Compression-Spinal Stenosis Market Report: Industry Manufacturers An …
Marketresearchfuture.com includes Global Spinal Cord Compression-Spinal Stenosis Market by indications, by diagnosis, by end users - Global Forecast till 2023 is new report.
Spinal cord compression is the second most frequent neurologic complication of cancer. Only in the United States, each year nearly 20,000 people with cancer develop spinal cord compression; this affected population represents 5% to 10% of the general cancer population.
Request Sample copy of Spinal cord compression-spinal stenosis…
Spinal Trauma Devices Market: Spinal Trauma Devices Sales to Surge Rapidly in Re …
The global spinal trauma devices market is dynamic and highly competitive. Only a couple of companies account for a substantial share in the market, thus lending it an oligopolistic vendor landscape. The market is largely dominated by DePuy Synthes, Medtronic, NuVasive, Inc., Stryker Corporation, and Globus Medical, Inc. The cumulative share of these companies added up to 79.1% in 2014, says Transparency Market Research (TMR) in a new report.
As…
Spinal Implants and Spinal Devices Market Analysis, Development and Demand Forec …
The global spinal implants and spinal devices market is growing, due to increasing demand for minimally invasive surgeries, increasing number of hospitals and surgical centers, and commercial applications in areas, such as nucleus arthroplasty, stem cell technology and artificial disk replacement. The spinal fusion and fixation technology dominates the market and the non-fusion/ motion preservation technology segment is expected to grow with the fastest rate during the forecast period, due…
